Obtenga las últimas noticias sobre las acciones de Plus Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de PSTV

Últimas noticias sobre

Plus Therapeutics

Plus Therapeutics Inc

POSTAL SVGS CHINA UNS/ADR by Postal Svgs Bk of China Ltd.

Postal Savings Bank Of China Co Ltd

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Annovis Bio

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Cibus

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Cue Biopharma

CEL-SCI

Evaxion

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

MiNK Therapeutics

IO Biotech

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Korro Bio

Kezar Life Sciences

LAVA Therapeutics

Medicus Pharma

Metagenomi

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Skye Bioscience

Senti Biosciences

TScan Therapeutics

Plus Therapeutics (PSTV) Previsión

Noticias

Beneficios

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Comments

Plus Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL